Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEpe Special Opp Regulatory News (ESO)

Share Price Information for Epe Special Opp (ESO)

Share Price is delayed by 15 minutes
Get Live Data
235.00    0.00 (0.00%)
Bid:
232.00
Ask:
238.00
Spread: 6.00 (2.586%)
Market Cap: £57.46m
ESO Live PriceLast checked at - London Stock Exchange

Intraday Epe Special Opp Share Chart

Investment

2 Dec 2021 07:15

RNS Number : 3513U
EPE Special Opportunities Limited
02 December 2021
 

EPE Special Opportunities Limited

 

Investment

 

EPE Special Opportunities Limited ("ESO" or the "Company") is pleased to announce that ESO Alternative Investments LP (an undertaking of ESO, in which it is the sole investor) ("ESO AI") has committed to invest a total of €10 million into EPIC Acquisition Corp ("EAC"), a newly incorporated special purpose acquisition company ("SPAC") and EAC's sponsor, EAC Sponsor Limited (the "Sponsor").

 

EAC today announced its intention to raise up to €150 million and its expected admission to listing and trading on Euronext Amsterdam on or around 6 December 2021 (the "IPO").

 

EAC intends to leverage the experience of EPIC Investment Partners LLP ("EPIC"), TT Bond Partners ("TTB") and their respective affiliates to identify, acquire and develop an innovative company operating in the consumer sector in the European Economic Area (the "EEA") or the United Kingdom which has the potential for significant growth in Asian markets (the "Business Combination"). EAC is targeting companies with an enterprise value of between €500 million and €1 billion.

 

The Sponsor is jointly led by EPIC, a UK-headquartered investment, advisory and administration firm which has 20 years' experience of using publicly-listed vehicles to make private equity investments, and TTB, a Hong Kong-based investment and advisory business which has extensive local relationships across Asia and a strong track record of helping global brands access and develop in Asian markets. EPIC is the Investment Advisor to ESO.

 

EAC will be supported by dedicated teams within EPIC and TTB. The combined platforms of EPIC and TTB span the UK, Hong Kong, Guernsey, Ireland and India and include c.250 employees, with 30 investment and advisory professionals.

 

The Sponsor has been formed to provide EAC with institutional leadership and resources, combining private equity and public markets investing experience, broad and highly active deal sourcing networks in Europe and Asia, operational leadership in the consumer sector and a deep and proven understanding of how global companies can succeed in Asian markets.

 

EAC will also benefit from the appointment of three independent non-executive directors with outstanding operating and financial track records. Stephan Borchert and Jan Zijderveld are both experienced public markets chief executive officers (CEOs), responsible for generating a collective c.$4 billion in shareholder value in the last three years through the sale of GrandVision (of which Mr Borchert is CEO) to EssilorLuxottica and the exit of Avon Products (of which Mr Zijderveld was CEO) to Natura & Co. Prior to his role at Avon Products, Mr Zijderveld was President and CEO of Unilever Europe. They are complemented by Nisha Kumar, an experienced CFO who will be the chair of EAC's Audit Committee. Ms Kumar has deep expertise in financial leadership, operations and corporate finance across public and private companies and private equity.

 

In combination, the Sponsor's investing, advisory and operating track record in Europe and Asia is expected to help EAC identify and successfully complete a Business Combination with a high-quality company in the EEA or the United Kingdom attracted by the unusual combination of investment capital and a track record of Asian market access and growth.

 

Subsequent to the Business Combination, the Sponsor will continue to actively support the growth of EAC, both through the implementation of organic initiatives and strategic acquisitions, most notably in local Asian markets where such acquisitions offer the potential to accelerate growth. The longer-term objective of both EAC and the Sponsor is to build a business at the forefront of consumer innovation, recognised in both its home markets and in Asia.

 

Further information on EAC can be found on the company's website, www.epicacquisitioncorp.com.

 

ESO's Investment

 

ESO is investing in both EAC and the Sponsor, which allows it to access potentially enhanced returns versus an investment solely in the IPO, as a result of the Sponsor's ownership of Class B ordinary shares ("Founder Shares") and warrants ("Founder Warrants") in EAC.

 

The Board of ESO believes that the potentially enhanced returns profile, combined with the opportunity to access larger and more geographically diverse companies through a liquid investment structure, means that the investment in EAC is attractive for the Company's shareholders.

 

Related Party Transaction

 

The transaction constitutes a related party transaction under Rule 13 of the AIM Rules.

 

The Board of ESO considers, having consulted with Numis as the Company's nominated adviser, that the terms of the transaction are fair and reasonable in so far as the Company's shareholders are concerned.

 

Inside Information

 

This announcement is made in accordance with Article 19 of the EU Market Abuse Regulation 596/2014.

 

The person responsible for releasing this information on behalf of the Company is Amanda Robinson of Langham Hall Fund Management (Jersey) Limited.

 

Enquiries:

 

EPIC Investment Partners LLP

+44 (0) 207 269 8860

James Henderson

Langham Hall Fund Management (Jersey) Limited

+44 (0) 153 488 5200

Amanda Robinson

Cardew Group Limited

+44 (0) 207 930 0777

Richard Spiegelberg

Numis Securities Limited

+44 (0) 207 260 1000

Nominated Advisor:

Stuart Skinner

Corporate Broker:

Charles Farquhar

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQTTBRTMTBMMBB
Date   Source Headline
5th Jun 20265:20 pmRNSUpdate on Share Buy Backs
5th Jun 20267:00 amRNSNet Asset Value(s)
4th Jun 20267:00 amRNSTransaction in Own Shares
3rd Jun 20267:00 amRNSTransaction in Own Shares
1st Jun 20265:00 pmRNSHolding(s) in Company
1st Jun 20264:25 pmRNSTransaction in Own Shares
1st Jun 20267:00 amRNSAnnouncement of Share Buy Backs
29th May 20261:30 pmRNSDirector/PDMR Shareholding
27th May 20264:00 pmRNSPartial Sell Down of Investment in Luceco plc
8th May 20267:00 amRNSNet Asset Value(s)
28th Apr 20265:05 pmRNSHolding(s) in Company
28th Apr 20265:00 pmRNSDirector/PDMR Shareholding
28th Apr 20267:15 amRNSDirector/PDMR Shareholding
23rd Apr 20267:15 amRNSHolding(s) in Company
16th Apr 20262:50 pmRNSHolding(s) in Company
16th Apr 20262:45 pmRNSDirector/PDMR Shareholding
15th Apr 20269:12 amRNSNet Asset Value(s)
14th Apr 20267:00 amRNSDirector/PDMR Shareholding
9th Apr 20267:00 amRNSDirector/PDMR Shareholding
25th Mar 20267:00 amRNSAnnual Financial Report
20th Feb 20266:22 pmRNSUpdate on Share Buy Backs
18th Feb 20261:00 pmRNSTransaction in Own Shares
17th Feb 20265:10 pmRNSHolding(s) in Company
17th Feb 20265:00 pmRNSHolding(s) in Company
17th Feb 20261:35 pmRNSTransaction in Own Shares
13th Feb 20267:00 amRNSAnnouncement of Share Buy Backs
9th Feb 20267:00 amRNSTrading Statement
4th Feb 20267:00 amRNSInterest Payment on Unsecured Loan Notes
15th Jan 20267:00 amRNSNet Asset Value(s)
22nd Dec 20257:00 amRNSUpdate on Share Buy Backs
22nd Dec 20257:00 amRNSUpdate on Share Buy Backs
11th Dec 20257:00 amRNSNet Asset Value(s)
4th Dec 20257:00 amRNSTransaction in Own Shares
2nd Dec 20257:03 amRNSTransaction in Own Shares
1st Dec 20257:00 amRNSTransaction in Own Shares
27th Nov 20257:08 amRNSTransaction in Own Shares
25th Nov 20257:00 amRNSTransaction in Own Shares
20th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSNet Asset Value(s)
13th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSTransaction in Own Shares
20th Oct 20257:00 amRNSTransaction in Own Shares
17th Oct 20257:00 amRNSDirector/PDMR Shareholding
17th Oct 20257:00 amRNSHolding(s) in Company
17th Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.